<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="in the subfamily Coronaviridae. CoVs are divided into four genera:" exact="alpha" post="(Î±), beta (Î²), gamma (Î³), and delta (Î´) (Figure"/>
 <result pre="of 10-30â€‰Î¼M [128]. Chloroquine, also a small molecule, is a" exact="quinine" post="analog used to prevent and treat malaria. Similar to"/>
 <result pre="analog used to prevent and treat malaria. Similar to umifenovir," exact="chloroquine" post="exhibits its inhibitory effect on influenza by pH stabilization."/>
 <result pre="chloroquine exhibits its inhibitory effect on influenza by pH stabilization." exact="Chloroquine" post="is a weak base and becomes protonated intracellularly in"/>
 <result pre="It can raise lysosomal pH to facilitate autophagy intracellularly [130â€&quot;132]." exact="Chloroquine" post="also alters the signaling pathway of enzymes, causing enzyme"/>
 <result pre="in host cells [133, 134]. Liu et al. claimed that" exact="chloroquine" post="could inhibit SARS-CoV entry by changing glycosylation of the"/>
 <result pre="vitro on primate cells and human rectal cells [136, 137]." exact="Hydroxychloroquine" post="is a derivative of chloroquine with an additional hydroxyl"/>
 <result pre="human rectal cells [136, 137]. Hydroxychloroquine is a derivative of" exact="chloroquine" post="with an additional hydroxyl group. These two chloroquines share"/>
 <result pre="Both have shown in vitro antiviral activities toward 2019-nCoV [138â€&quot;140]." exact="Hydroxychloroquine" post="was more effective than chloroquine in inhibiting 2019-nCoV in"/>
 <result pre="antiviral activities toward 2019-nCoV [138â€&quot;140]. Hydroxychloroquine was more effective than" exact="chloroquine" post="in inhibiting 2019-nCoV in vitro on primate cells [141]."/>
 <result pre="inhibiting 2019-nCoV in vitro on primate cells [141]. Until now," exact="chloroquine" post="has shown apparent efficiency and safety against 2019-nCoV in"/>
 <result pre="against 2019-nCoV in clinical trials conducted in China [139]. Currently," exact="chloroquine" post="or hydroxychloroquine has been administered to hospitalized 2019-nCoV patients"/>
 <result pre="in clinical trials conducted in China [139]. Currently, chloroquine or" exact="hydroxychloroquine" post="has been administered to hospitalized 2019-nCoV patients on an"/>
 <result pre="and the USA [42]. However, it must be noted that" exact="chloroquine" post="and hydroxychloroquine cause ocular toxicity [142]. Hydroxychloroquine is reportedly"/>
 <result pre="USA [42]. However, it must be noted that chloroquine and" exact="hydroxychloroquine" post="cause ocular toxicity [142]. Hydroxychloroquine is reportedly less toxic"/>
 <result pre="be noted that chloroquine and hydroxychloroquine cause ocular toxicity [142]." exact="Hydroxychloroquine" post="is reportedly less toxic than chloroquine, making it more"/>
 <result pre="In vivo studies on rats with pancreatic fibrosis showed that" exact="camostat" post="mesylate inhibits inflammation, cytokine expression, and fibrosis in the"/>
 <result pre="the viral MERS-CoV particle [156]. Zhou et al. claimed that" exact="camostat" post="mesylate displays an inhibitory effect in mice for SARS-CoV"/>
 <result pre="treatment [113]. Unfortunately, in vitro and in vivo data for" exact="camostat" post="mesylate against coronaviruses are limited. More investigation is required"/>
 <result pre="against coronaviruses are limited. More investigation is required to evaluate" exact="camostat" post="mesylate as a potential therapeutic against COVID-19. Lopinavir-ritonavir is"/>
 <result pre="a coformulated antiretroviral drug with excellent efficacy against HIV-1. The" exact="lopinavir" post="has a core molecular structure identical to ritonavir. The"/>
 <result pre="to ritonavir. The 5-thiazolyl end group and 2-isopropylthiazolyl group in" exact="ritonavir" post="are replaced by the phenoxyacetyl group and a modified"/>
 <result pre="the amino terminus has six-membered cyclic urea attached. In brief," exact="lopinavir" post="is a potent protease inhibitor developed from ritonavir with"/>
 <result pre="In brief, lopinavir is a potent protease inhibitor developed from" exact="ritonavir" post="with high specificity for HIV-1 protease [103]. It represents"/>
 <result pre="the production of noncontagious viral particles. On the other hand," exact="ritonavir" post="binds to HIV-1 protease, interrupting the maturation and production"/>
 <result pre="Hong Kong has shown that the combination of lopinavir-ritonavir and" exact="ribavirin" post="treatment for 152 patients against SARS-CoV had an overall"/>
 <result pre="attractive therapeutic target to prevent host cells from producing viruses." exact="Ribavirin" post="is a synthetic guanosine nucleoside analog that mimics purines,"/>
 <result pre="nucleoside analog that mimics purines, including inosine and adenosine, and" exact="ribavirin" post="has been used in the treatment of respiratory syncytial"/>
 <result pre="at the heterocyclic base, compared with guanine's two rings. Notably," exact="ribavirin" post="has a ribose sugar moiety with a hydroxyl group"/>
 <result pre="2â€²-carbon position, enabling preferential activity in RNA-related metabolism [168, 169]." exact="Ribavirin" post="inhibits cellular enzyme and inosine monophosphate dehydrogenase involved in"/>
 <result pre="inosine monophosphate dehydrogenase involved in purine nucleotide biosynthesis [170, 171]." exact="Ribavirin" post="is also known for its inhibitory effect on viruses"/>
 <result pre="catastrophically error-prone. It is likely that as a nucleoside analog," exact="ribavirin" post="is incorporated by RdRp into the newly synthesized viral"/>
 <result pre="synthesized viral genome, where it induces mutagenesis [170, 172]. Although" exact="ribavirin" post="has proven effective against viral infections, its mechanism of"/>
 <result pre="proposed mechanisms of action that require further validation [168, 173]." exact="Ribavirin" post="was initially used in treating SARS; however, ribavirin treatment"/>
 <result pre="[168, 173]. Ribavirin was initially used in treating SARS; however," exact="ribavirin" post="treatment lacked an in vitro antiviral effect and caused"/>
 <result pre="effects including anemia, hypoxemia, and decreased hemoglobin levels [174]. However," exact="ribavirin" post="was used as the primary treatment during the MERS"/>
 <result pre="during the MERS outbreak [175]. In general, clinical studies of" exact="ribavirin" post="treatment for SARS and MERS did not show strong"/>
 <result pre="studies of ribavirin's efficacy against COVID-19. Therefore, the use of" exact="ribavirin" post="remains controversial and requires more investigation for a better"/>
 <result pre="in which it shares the same carboxamide moiety [180]. While" exact="ribavirin" post="interacts with the viral polymerase directly, favipiravir must be"/>
 <result pre="and safety in 2019-nCoV treatment. Remdesivir is a trial synthetic" exact="adenosine" post="analog that has not yet been clinically approved [185]."/>
 <result pre="therapeutic efficacy against coronavirus outbreaks, umifenovir, chloroquine, hydroxychloroquine, lopinavir-ritonavir, and" exact="ribavirin" post="have been recommended in the latest guidelines for diagnosis"/>
 <result pre="as a possible treatment for COVID-19. On the other hand," exact="ivermectin" post="is originally a medication used to treat parasite infestation."/>
 <result pre="nuclear protein import cycle [196]. Caly et al. reported that" exact="ivermectin" post="successfully inhibited 2019-nCoV in vitro but the mechanism of"/>
 <result pre="vitro but the mechanism of action is unclear [197]. Since" exact="ivermectin" post="is an approved drug, it shows great potential as"/>
 <result pre="reported that the Smabucus Formosana Nakai (a traditional medicinal herb)" exact="ethanol" post="stem extract displayed strong anti-HCoV-NL63 activity [227]. Moreover, TCM"/>
 <result pre="coronavirus disease 2019 (COVID-19)Drug Discoveries &amp;amp; Therapeutics2020141586010.5582/ddt.2020.0101232147628 129SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesThe"/>
 <result pre="mouse peritoneal macrophagesJournal of Cell Biology198190366566910.1083/jcb.90.3.6656169733 131SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNature Reviews Rheumatology202016315516610.1038/s41584-020-0372-x32034323 132MautheM.OrhonI.RocchiC.et al.Chloroquine"/>
 <result pre="coronavirus by chloroquineBiochemical and Biophysical Research Communications2004323126426810.1016/j.bbrc.2004.08.08515351731 138WangM.CaoR.ZhangL.et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research202030326927110.1038/s41422-020-0282-032020029 139GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="of COVID-19 associated pneumonia in clinical studiesBioScience Trends2020141727310.5582/bst.2020.0104732074550 140ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19International Journal of Antimicrobial"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="2 (SARS-CoV-2)Clinical Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic exposure to" exact="hydroxychloroquine" post="or chloroquine on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity"/>
 <result pre="Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic exposure to hydroxychloroquine or" exact="chloroquine" post="on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity and pharmacokinetics"/>
 <result pre="on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateThe American Journal of Medicine1983751111810.1016/0002-9343(83)91265-26408923 144KonvalinkaJ.KrÃ¤usslichH.-G.MÃ¼llerB.Retroviral proteases and their"/>
 <result pre="al.Protease inhibitors targeting coronavirus and filovirus entryAntiviral Research2015116768410.1016/j.antiviral.2015.01.01125666761 153AshizawaN.HashimotoT.MiyakeT.ShizukuT.ImaokaT.KinoshitaY.Efficacy of" exact="camostat" post="mesilate compared with famotidine for treatment of functional dyspepsia:"/>
 <result pre="and filovirus entryAntiviral Research2015116768410.1016/j.antiviral.2015.01.01125666761 153AshizawaN.HashimotoT.MiyakeT.ShizukuT.ImaokaT.KinoshitaY.Efficacy of camostat mesilate compared with" exact="famotidine" post="for treatment of functional dyspepsia: is camostat mesilate effective?Journal"/>
 <result pre="mesilate compared with famotidine for treatment of functional dyspepsia: is" exact="camostat" post="mesilate effective?Journal of Gastroenterology and Hepatology200621476777110.1111/j.1440-1746.2005.04041.x16677167 154GiboJ.ItoT.KawabeK.et al.Camostat mesilate"/>
 <result pre="and pancreatic stellate cells activityLaboratory Investigation2005851758910.1038/labinvest.370020315531908 155IshikuraH.NishimuraS.MatsunamiM.et al.The proteinase inhibitor" exact="camostat" post="mesilate suppresses pancreatic pain in rodentsLife Sciences200780211999200410.1016/j.lfs.2007.02.04417433371 156ShiratoK.KawaseM.MatsuyamaS.Middle East"/>
 <result pre="Medicine20203821787179910.1056/NEJMoa200128232187464 162ChenJ.LiangZ.WangW.YiC.ZhangS.ZhangQ.Revealing origin of decrease in potency of darunavir and" exact="amprenavir" post="against HIV-2 relative to HIV-1 protease by molecular dynamics"/>
 <result pre="America201411133122341223910.1073/pnas.140002711125092296 164LinS.ShenR.HeJ.LiX.GuoX.Molecular modeling evaluation of the binding effect of ritonavir," exact="lopinavir" post="and darunavir to severe acute respiratory syndrome coronavirus 2"/>
 <result pre="Virology202092669369710.1002/jmv.2576132167173 168ThomasE.GhanyM. G.LiangT. J.The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntiviral Chemistry and Chemotherapy201223111210.3851/IMP212522592135 169CrottyS.MaagD.ArnoldJ."/>
 <result pre="CAntiviral Chemistry and Chemotherapy201223111210.3851/IMP212522592135 169CrottyS.MaagD.ArnoldJ. J.et al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNature Medicine20006121375137910.1038/82191 170DulinD.ArnoldJ. J.van LaarT.et"/>
 <result pre="United States of America200198126895690010.1073/pnas.11108559811371613 173TeH. S.RandallG.JensenD. M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterology &amp;amp; Hepatology20073321822521960835"/>
 <result pre="dengue virusBiochemical Journal2012443385185610.1042/BJ2012015022417684 197CalyL.DruceJ. D.CattonM. G.JansD. A.WagstaffK. M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Research2020178, article"/>
 <result pre="Clinical Virology200841212212810.1016/j.jcv.2007.10.01118036887 227WengJ.-R.LinC. S.LaiH. C.et al.Antiviral activity of Sambucus FormosanaNakai" exact="ethanol" post="extract and related phenolic acid constituents against human coronavirus"/>
 <result pre="with favipiravir (see favipiravir) Currently being evaluated in China Chloroquine," exact="hydroxychloroquine" post="Entry receptor Antiviral drug on malaria; not yet tested"/>
 <result pre="Not known None Lopinavir-ritonavir Viral protease Used in combination with" exact="ribavirin" post="for SARS and MERS N/A 199 hospitalized patients, Wuhan,"/>
 <result pre="drug; not yet tested for coronaviruses N/A Not known None" exact="Ribavirin" post="Genome replication Used in combination with lopinavir-ritonavir for SARS"/>
</results>
